Megan Healey, PhD, MPH is a molecular epidemiologist with expertise in epigenetics and breast cancer. Dr. Healey uses population-based studies to investigate molecular determinants of cancer subtypes and prognosis. Trained as a bench scientist, Dr. Healey completed research fellowships in cancer epigenetics at Johns Hopkins and cancer epidemiology at Harvard. She transitioned from biomedical science to public health in hopes of leveraging her interdisciplinary background to improve the health of populations. Part of that mission is to help train our future leaders in public health. Dr. Healey is invested in bringing innovative, integrated and practical approaches to learning in the classroom, particularly in large courses. Currently, Dr. Healey teaches Quantitative Methods for Public Health, Concepts and Methods in Epidemiology, and Cancer Epidemiology. She is the recipient of the BUSPH Educational Innovation Award and several BUSPH Excellence in Teaching Awards. Dr. Healey is the Director of MPH Programs.
- Johns Hopkins University School of Medicine, PhD Field of Study: Molecular Medicine
- Harvard School of Public Health, MPH Field of Study: Quantitative Methods
- Clark University, BA Field of Study: Biochemistry
- Published on 5/1/2019
Werler MM, Stuver SO, Healey MA, LaMorte WW. The Future of Teaching Epidemiology. Am J Epidemiol. 2019 05 01; 188(5):825-829. PMID: 30865216.
- Published on 8/8/2017
Healey MA, Hirko KA, Beck AH, Collins LC, Schnitt SJ, Eliassen AH, Holmes MD, Tamimi RM, Hazra A. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study. Breast Cancer Res Treat. 2017 Nov; 166(2):613-622. PMID: 28791482.
- Published on 1/1/2017
Healy MA. A "microounce" of cancer prevention. Public Health Post. 2017.
- Published on 9/16/2014
Healey MA, Hu R, Beck AH, Collins LC, Schnitt SJ, Tamimi RM, Hazra A. Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study. Breast Cancer Res Treat. 2014 Oct; 147(3):639-51. PMID: 25224916.
- Published on 2/1/2013
Hossain MZ, Healey MA, Lee C, Poh W, Yerram SR, Patel K, Azad NS, Herman JG, Kern SE. DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells. Oncotarget. 2013 Feb; 4(2):298-309. PMID: 23593653.
- Published on 4/1/2011
Xu L, Wang SS, Healey MA, Faupel-Badger JM, Wilken JA, Battaglia T, Szabo E, Mao JT, Bergan RC. The Ninth Annual American Association of cancer research international conference on frontiers in cancer prevention research. Cancer Prev Res (Phila). 2011 Apr; 4(4):616-21. PMID: 21464034.
- Published on 7/1/2010
Healey MA, Deaton SL, Alder JK, Winnepenninckx V, Casero RA, Herman JG. Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma. Epigenetics. 2010 Jul 1; 5(5):410-21. PMID: 20484992.
- Published on 9/1/2008
Cummings SD, Ryu B, Samuels MA, Yu X, Meeker AK, Healey MA, Alani RM. Id1 delays senescence of primary human melanocytes. Mol Carcinog. 2008 Sep; 47(9):653-9. PMID: 18240291.
- Published on 10/15/2007
Ryu B, Kim DS, DeLuca AM, Healey MA, Dunlap S, Fackler MJ, Herman J, Alani RM. Id1 expression is transcriptionally regulated in radial growth phase melanomas. Int J Cancer. 2007 Oct 15; 121(8):1705-9. PMID: 17565736.
- Published on 1/1/2004
Esni F, Ghosh B, Biankin AV, Lin JW, Albert MA, Yu X, MacDonald RJ, Civin CI, Real FX, Pack MA, Ball DW, Leach SD. Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development. 2004; 131(17):4213-24.
News & In the Media
- Published on September 15, 2022
- Published on May 12, 2022
- Published on July 17, 2020
- Published on June 14, 2017